Foldable IOLs: dislocation most common explant cause

Article

Dislocation and decentration are, overall, the most common reasons for foldable intraocular lens (IOL) explantation, and the incidence of these complications is rising.

Dislocation and decentration are, overall, the most common reasons for foldable intraocular lens (IOL) explantation, and the incidence of these complications is rising, said Nick Mamalis, MD of the John Moran Centre, University of Utah, USA. Other major causes for explantation are glare and optical aberrations, incorrect lens power and calcification of hydrophilic (hydrogel) IOLs, according to Dr Mammalis.

These are the latest results of the ASCRS/ESCRS survey on foldable IOLs requiring explantation or secondary intervention. This annual survey is now in its ninth year.

"The most common complications involving foldable IOLs have changed very little over the last three years and may continue to be avoided by excellent surgical technique, quality manufacturing, careful IOL folding and insertion, and accurate IOL measurements," Dr Mamalis noted.

The survey comes from questionnaires filled out by contributing surgeons each time they explant a foldable IOL. It discovered that complications vary according to the type of foldable IOL. Dislocation and decentration was the most common complication associated with one-piece silicone IOLs.

Similarly, dislocation/decentration was the most common cause of explantation for three piece silicone, three-piece acrylic and one-piece acrylic IOLs, followed by glare and other optical aberrations. Calcification or opacification was the most common cause of hydrophilic acrylic IOL explantation.

Over the nine years of the survey, the incidence of dislocation decentration has increased.

Dr Mamalis concluded with a plea to surgeons to complete the questionnaire whenever they explant a foldable IOL. The survey is available on the ASCRS website.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.